Baird Financial Group, Inc. Editas Medicine, Inc. Transaction History
Baird Financial Group, Inc.
- $54.4 Billion
- Q2 2025
A detailed history of Baird Financial Group, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 28,871 shares of EDIT stock, worth $86,901. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,871
Previous 30,751
6.11%
Holding current value
$86,901
Previous $35,000
80.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EDIT
# of Institutions
214Shares Held
45.4MCall Options Held
476KPut Options Held
338K-
Black Rock Inc. New York, NY7.78MShares$23.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$21.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$5.91 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$5.65 Million0.0% of portfolio
-
State Street Corp Boston, MA1.85MShares$5.56 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $207M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...